|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ Print-friendly version ] |
| Antiplatelet therapy tailoring after primary percutaneous coronary intervention (PCI) |
| ISRCTN | ISRCTN64082539 |
| ClinicalTrials.gov identifier | |
| Public title | Antiplatelet therapy tailoring after primary percutaneous coronary intervention (PCI) |
| Scientific title | Antiplatelet Regimen Tailoring after primary Percutaneous Coronary Intervention (ART-PCI): a single centre longitudinal cohort prospective trial |
| Acronym | ART-PCI |
| Serial number at source | 553/12 |
| Study hypothesis | Assessment of platelet residual aggregation (APRA) may help to identify patients at increased risk for major thrombotic events after primary percutaneous coronary intervention (pPCI), who may benefit from antiplatelet regimen tailoring (ART). |
| Lay summary | |
| Ethics approval | Ethics Committee of the Clinical Center of Serbia approved on the 2nd June 2009 (ref: 553/12) |
| Study design |
Single centre observational longitudinal cohort prospective trial
|
| Countries of recruitment | Serbia |
| Disease/condition/study domain | ST-elevation myocardial infarction (STEMI) |
| Participants - inclusion criteria |
1. ST-elevation myocardial infection (STEMI) patients undergoing primary PCI in our institution
2. Both genders, aged greater than 18 years 3. Platelet residual aggregation (PRA) assessed 24 hours after the loading with clopidogrel 600 mg 4. Control group: 1000 patients enrolled in the RISK-PCI trial (see http://www.controlled-trials.com/ISRCTN83474650) in our centre from February 1st, 2006 till June 1st, 2008, who did not have platelet function assays Low responders to clopidogrel will be subjected to ART if there is no exclusion criteria for ART. |
| Participants - exclusion criteria |
1. Not alive until 24 hours from clopidogrel loading 600 mg
2. Aged greater than 75 years 3. Percutaneous balloon angioplasty (POBA) without stenting 4. Failed pPCI 5. Active bleeding in hospital 6. Coronary dissection with pericardial collection 7. Haemoglobin (Hb) less than 80 g/dL needing transfusion in hospital 8. Simultaneous treatment with oral anticoagulants 9. Candidates for urgent bypass surgery 10. Low basal thrombin receptor activating peptide (TRAP) value (less than 500 AU/minute) 11. Hystory of recent bleeding from ulcer 12. Thrombocyte count less than 100,000/ml 13. Drug non-compliance 14. Withdrawal of consent |
| Anticipated start date | 01/06/2008 |
| Anticipated end date | 28/02/2010 |
| Status of trial | Completed |
| Patient information material | Not available in web format, please use the contact details below to request a patient information sheet |
| Target number of participants | 700 patients in the ART group and 1000 patients in the control group |
| Interventions |
Multiple electrode aggregometry (MEA) is performed using an impedance aggregometer (Multiplate analyzer, Dynabyte GmbH, Munich, Germany). Whole blood is sampled 24 hours after the procedure and placed in 7 ml plastic tubes containing the anticoagulant heparin (50 U/ml). For patients who received IIb/IIIa inhibitor tirofiban, blood samples are obtained at least 24 hours after the completition of tirofiban infusion. Blood samples are stored on the room temperature for 30 minutes, diluted (1:2) with 0.9% NaCl solution and incubated on 37 +/- 0.5 °C for 3 minutes, using a computer-controlled electronic pipette.
ASPI test is used to detect the effect of aspirin using the ciclooxygenase substrate arachidonic acid (final concentration 0.5 mM/L). ADP test is used to assess the blockade of ADP receptor by clopidogrel. Aggregation is continuously recorded for 6 minutes after ADP (final concentration 6.4 gM/L) is added. PGE1, as a suppressor of intracellular free calcium, is simultaneously added to increase the test's sensitivity to ADP. The increase of impedance is transformed to aggregation units (AU) that are plotted against time as area under the curve (AU/min). TRAP test resembles direct activation of the thrombin receptor using the thrombin receptor activating peptide (final concentration 32 gM/L). PRA above 50%, compared to the basal value estimated by TRAP test, is linked with low responding (LR) to clopidogrel. A 150 mg daily clopidogrel is instituted in low-responders (LRs) during the first 30 days after the procedure. The second APRA is obtained 7 days after the first test. In LRs, the 500 mg maintenance dose of ticlopidine is administrated instead of clopidogrel. A 300 mg aspirin daily is administrated during the next 30 days to all patients without contraindications. After 30 days, the doses will be reduced to 100 mg aspirin and 75 mg clopidogrel. Patients will be followed-up at 30 days and 1 year after enrolment by telephone interviews and/or outpatient visits. Interviewers will be blinded to the results of platelet aggregation. An independent Clinical Event Committee will adjudicate the occurrence of the major events and major bleeding. Safety data will be reviewed monthly by an independent Safety Monitoring Committee. Statistical analyses will be performed by the Institute for Medical Statistics and Informatics, School of Medicine, Belgrade, Serbia. Statistical analysis: Continuous variables are expressed as median values with 25th and 75th quartiles, whereas categorical variables are expressed as frequency and percentage. Analysis for normality of data are performed using the Kolmogorov-Smirnov test. Baseline differences between groups are analysed using the independent Student t-test or Mann-Whitney test for continuous variables, and Pearson X2 test for categorical variables. Univariable logistic regression model is used to identify risk factors influencing clinical outcomes at 30-day follow-up. Time-to-event outcomes are presented using Kaplan-Meier curves; differences between groups are compared using a 2-sided log-rank test. Multivariate logistic regression analysis will be performed to identify independent predictors of high PRA as dependent variables. Variables are selected by backward method with a P-value of less than 0.1 as entry criterion. The cut-off values for significant predictors are determined using receiver operating characteristic (ROC) analysis. |
| Primary outcome measure(s) |
Efficacy outcome:
Major adverse cardiovascular events (MACE). MACE comprises death, nonfatal reinfarction, ischaemic stroke and target vessel revascularisation (TVR). Nonfatal reinfarction is defined as the presence of at least two of the three following criteria: 1. Recurrent ischaemic chest pain longer than 20 minutes 2. Reoccurrence of ST elevation greater than 0.1 mV or new pathognomonic Q waves in at least two contiguous leads, and 3. Increase of cardiac troponin over the upper reference limit (URL) and over 50% of the lowest recovery level from the index myocardial infaction (MI) The more than triple URL value of cardiac troponin after PCI is defined as PCI-related myocardial infarction. Stroke is defined as a new onset of focal or global neurological deficit lasting more than 24 hours, and is computed tomography (CT)-classified as ischaemic. Haemorrhagic stroke is counted as life-threatening bleeding and is not included into stroke analyses. Target-vessel revascularisation is defined as ischaemia-driven revascularisation of the infarction-related artery during the follow-up period. Safety outcome: Major bleeding. Bleeding events were classified according to Thrombolysis In Myocardial Infarction (TIMI) criteria. All primary and secondary endpoints will be recorded at 1 month and at 1 year after the enrolment. |
| Secondary outcome measure(s) | Subacute stent thrombosis. All primary and secondary endpoints will be recorded at 1 month and at 1 year after the enrolment. |
| Sources of funding |
Clinical Centre of Serbia (Serbia)
|
| Trial website | |
| Publications | |
| Contact name | Prof Igor Mrdovic |
| Address | Pasterova 2 |
| City/town | Beograd |
| Zip/Postcode | 11000 |
| Country | Serbia |
| Tel | +38 (0)11 6346 2488 |
| Fax | +38 (0)11 1366 2364 |
| igormrd@gmail.com | |
| Sponsor | Clinical Centre of Serbia (Serbia) |
| Address | Pasterova 2 |
| City/town | Beograd |
| Zip/Postcode | 11000 |
| Country | Serbia |
| Tel | +38 (0)11 1361 8444 |
| Fax | +38 (0)11 1264 4667 |
| cdcc@klinicki-centar.rs | |
| Sponsor website: | http://www.klinicki-centar.rs |
| Date applied | 08/02/2010 |
| Last edited | 18/02/2010 |
| Date ISRCTN assigned | 18/02/2010 |
|
|
|
|
|
| © 2012 ISRCTN unless otherwise stated. | |
|
|
|
|